Ranibizumab gains NICE approval for secondary macular oedema

Ranibizumab (Lucentis) can now be prescribed in the NHS for macular oedema secondary to central or branch retinal vein occlusion.

Ranibizumab is administered by specialists via intravitreal injection (pictured) | SCIENCE PHOTO LIBRARY
Ranibizumab is administered by specialists via intravitreal injection (pictured) | SCIENCE PHOTO LIBRARY

Ranibizumab can be used for macular oedema both as first-line therapy following central retinal vein occlusion and as a second-line treatment for branch retinal vein occlusion when laser photocoagulation has not been beneficial or cannot be used owing to the extent of macular haemorrhage. However, it must be provided by the manufacturer at a discount as agreed in the patient access scheme.

This recommendation follows recent positive decisions by NICE on the use of ranibizumab in wet age-related macular degeneration and diabetic macular oedema, after the implementation of a patient access sceme in 2012 reducing the cost of the drug to the NHS.

View Lucentis drug record

NICE guidance on ranibuzumab in macular oedema secondary to retinal vein occlusion 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases